Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial

We recently published 11 Best Cancer Stocks to Buy Right Now. Arcellx, Inc. stands sixth among them.

Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company developing next-generation cell therapies to treat cancer and incurable diseases, with a focus on improving the safety and efficacy of CAR-T treatments through its proprietary D-Domain and ddCAR platforms.

Its lead candidate, anitocel, for multiple myeloma has shown exceptional Phase 2 trial results, with a 97% overall response rate and 93.1% minimal residual disease (MRD)-negative responses. Importantly, the therapy demonstrated a favorable safety profile, avoiding severe neurotoxicity often associated with CAR-T treatments. Over 150 patients have been treated, with long-term data confirming strong efficacy and tolerability. To align with FDA guidance, Arcellx, Inc. (NASDAQ:ACLX) has updated its iMMagine-3 study protocol to include MRD negativity alongside progression-free survival as dual primary endpoints, aiming to accelerate regulatory approval and patient access.

The company will present updated results from 117 patients in the iMMagine-1 trial at the European Hematology Association (EHA) 2025, reinforcing its commitment to transparency and innovation. A commercial launch of anito-cel is targeted for 2026, supported by new leadership additions to strengthen operational and strategic execution.

The business has also expanded its partnership with Kite (a Gilead company) to co-develop and co-commercialize CAR-T programs for multiple myeloma and lymphoma. The collaboration, backed by significant funding, underscores confidence in Arcellx, Inc. (NASDAQ:ACLX)’s pipeline and its potential to address high unmet needs in oncology.

Beyond anito-cel, the corporation is advancing programs like ACLX-001 (ARC-SparX), designed to enhance flexibility and control in CAR-T therapies.

While we acknowledge the potential of ACLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.